Sorli C, Harashima S-I, Tsoukas GM et al (2017) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
If you have medical records documenting gastroparesis, intestinal blockage, or vision loss that developed while taking or shortly after stopping semaglutide medications, you may qualify to file an Ozempic lawsuit and seek compensation
As a GLP-1 receptor agonist, semaglutide has been shown to improve blood sugar control in individuals with type 2 diabetes
At MARC, weve built the right setup to manage these challenges with confidence
What should I be aware of when taking Ozempic